구강암 세포에서 혈관내피성장인자 수용체-3 억제제의 항종양 효과 = Anti-tumor Effects of Vascular Endothelial Growth Factor Receptor-3 Inhibitor on Oral Cancer Cells

다국어 초록 (Multilingual Abstract)

Purpose: Vascular endothelial growth factor (VEGF) plays a key role in tumor angiogenesis and lymphangiogenesis including induction of endothelial cell proliferation, migration and capillary tube formation. E7080 (S1164, Selleck chemical, Houston, TX, USA) is a muti-targeted kinase inhibitor, which targets VEGF receptor-2, 3 (VEGFR-2, 3) and inhibits survival and proliferation of tumor cell. The purpose of this study was to determine the anti-tumor effect of E7080 on oral squamous cell carcinoma. Methods: An oral squamous cell carcinoma cell line, SCC-9 was used in this study. E7080 was applied to SCC-9 cells by 3 different concentrations (1, 5, 10 ${\mu}g/mL$). Control means no application of E7080. The cellular growth was evaluated by real-time cell electronic sensing and MTT assay. The signal transduction was evaluated by Western blotting. Results: In experimental group, SCC-9 cell proliferation was decreased and the VEGFR-3 downstream pathways were inhibited compared with control. Furthermore, increasing the concentration of E7080, the ability of E7080 to disturbance of SCC-9 cell proliferation was increased. Conclusion: Proliferation of SCC-9 cells was inhibited by E7080, which was through by inhibition of VEGFR-3 downstream pathway. In vivo study with E7080 will be required to provide therapeutic benefits in oral squamous cell carcinoma.

참고문헌 (Reference)

1 박영욱, "구강암에서 림프관형성 인자의 발현에 관한 면역조직화학적 연구" 대한악안면성형재건외과학회 32 (32): 1-8, 2010

2 Yancopoulos GD, "Vascular-specific growth factors and blood vessel formation" 407 : 242-248, 2000

3 Dvorak HF, "Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy" 20 : 4368-4380, 2002

4 Dvorak HF, "Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis" 146 : 1029-1039, 1995

5 Fontanini G, "Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma" 3 : 861-865, 1997

6 Ferrara N, "Vascular endothelial growth factor as a target for anticancer therapy" 9 (9): 2-10, 2004

7 Masood R, "Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors" 98 : 1904-1913, 2001

8 Kerbel RS, "Tumor angiogenesis: past, present and the near future" 21 : 505-515, 2000

9 Su JL, "The role of the VEGF-C/VEGFR-3 axis in cancer progression" 96 : 541-545, 2007

10 Fidler IJ, "The implications of angiogenesis for the biology and therapy of cancer metastasis" 79 : 185-188, 1994

11 Moser C, "The direct effects of anti- vascular endothelial growth factor therapy on tumor cells" 6 : 564-571, 2007

12 Dennis PA, "Studies on the role of basic fibroblast growth factor in vivo: inability of neutralizing antibodies to block tumor growth" 144 : 84-98, 1990

13 Gospodarowicz D, "Structural characterization and biological functions of fibroblast growth factor" 8 : 95-114, 1987

14 Benjamin LE, "Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal" 103 : 159-165, 1999

15 Volm M, "Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer" 74 : 64-68, 1997

16 Kyzas PA, "Prognostic significance of VEGF immunohistochemical expression and tumor angiogenesis in head and neck squamous cell carcinoma" 131 : 624-630, 2005

17 Gospodarowicz D, "Production a corpus luteum angiogenic factor responsible for proliferation of capillaries and neovascularization of the corpus luteum" 75 : 847-851, 1978

18 Esch F, "Primary structure of bovine pituitary basic fibroblast growth factor (FGF) and comparison with the amino-terminal sequence of bovine brain acidic FGF" 82 : 6507-6511, 1985

19 Shweiki D, "Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis" 91 : 2235-2243, 1993

20 Hanahan D, "Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis" 86 : 353-364, 1996

21 Matsui J, "Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase" 14 : 5459-5465, 2008

22 Matsuzaki K, "Monoclonal antibodies against heparin-binding growth factor II/basic fibroblast growth factor that block its biological activity: invalidity of the antibodies for tumor angiogenesis" 86 : 9911-9915, 1989

23 Jain RK, "Molecular regulation of vessel maturation" 9 : 685-693, 2003

24 Karkkainen MJ, "Lymphatic endothelium: a new frontier of metastasis research" 4 : 2-5, 2002

25 Folkman J, "Isolation of a tumor factor responsible for angiogenesis" 133 : 275-288, 1971

26 Jaye M, "Human endothelial cell growth factor: cloning, nucleotide sequence, and chromosome localization" 233 : 541-545, 1986

27 Brown LF, "Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer" 26 : 86-91, 1995

28 Brown LF, "Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract" 53 : 4727-4735, 1993

29 Xia G, "Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer" 175 : 1245-1252, 2006

30 Vlodavsky I, "Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into subendothelial extracellular matrix" 84 : 2292-2296, 1987

31 Matsui J, "E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition" 122 : 664-671, 2008

32 Ikuta K, "E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles" 15 : 7229-7237, 2009

33 Glen H, "E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion" 11 : 309-, 2011

34 Ogino H, "E7080 suppresses hematogenous multiple organ metastases of lung cancer cells with nonmutated epidermal growth factor receptor" 10 : 1218-1228, 2011

35 Salameh A, "Direct recruitment of CRK and GRB2 to VEGFR-3 induces proliferation, migration, and survival of endothelial cells through the activation of ERK, AKT, and JNK pathways" 106 : 3423-3431, 2005

36 Jakeman LB, "Developmental expression of binding sites and messenger ribonucleic acid for vascular endothelial growth factor suggests a role for this protein in vasculogenesis and angiogenesis" 133 : 848-859, 1993

37 Vaisman N, "Characterization of the receptors for vascular endothelial growth factor" 265 : 19461-19466, 1990

38 Jakeman LB, "Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues" 89 : 244-253, 1992

39 Folkman J, "Angiogenic factors" 235 : 442-447, 1987

40 Carmeliet P, "Angiogenesis in cancer and other diseases" 407 : 249-257, 2000